Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study will treat patients with previously untreated high grade myleodysplastic syndromes
(MDS) with both omacetaxine mepesuccinate and azacitidine.